{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:38Z","timestamp":1792686098302,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajpc.2025.101311","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:46:38Z","timestamp":1758620798000},"page":"101311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association between proprotein convertase subtilisin\/kexin type 9 targeted therapies and the risk of arrhythmias: a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novonil","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishat","family":"Shama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kripa","family":"Rajak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulochana","family":"Khadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibadete","family":"Byty\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ajpc.2025.101311_bib0001","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101311_bib0002","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjmed.2022.02.016","article-title":"Effect of Alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from the ODYSSEY OUTCOMES trial","volume":"135","author":"Lopes","year":"2022","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101311_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrcardio.2010.3","article-title":"Sudden cardiac death: epidemiology and risk factors","volume":"7","author":"Adabag","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101311_bib0004","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/jcm12031075","article-title":"Atrial fibrillation and the risk of ventricular arrhythmias and cardiac arrest: a nationwide population-based study","volume":"12","author":"Fawzy","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.ajpc.2025.101311_bib0005","series-title":"StatPearls","article-title":"Acute coronary syndrome","author":"Singh","year":"2025"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101311_bib0006","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2125.2012.04258.x","article-title":"The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"74","author":"Fang","year":"2012","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.ajpc.2025.101311_bib0007","article-title":"Cardiovascular safety of Patisiran among transthyretin cardiac amyloidosis: a meta-analysis","author":"Jaiswal","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ajpc.2025.101311_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcad.2024.04.001","article-title":"Association between testosterone replacement therapy and cardiovascular outcomes: a meta-analysis of 30 randomized controlled trials","volume":"85","author":"Jaiswal","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101311_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-024-00689-7","article-title":"Efficacy of colchicine for prevention of stroke and adverse cardiovascular events: a meta-analysis of 16 randomized controlled trials","volume":"25","author":"Jaiswal","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ajpc.2025.101311_bib0010","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101311_bib0011","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101311_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ajpc.2025.101311_bib0013","series-title":"Stata Statistical Software: Release 18","year":"2023"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101311_bib0014","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of Bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101311_bib0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","article-title":"Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab","volume":"12","author":"Ridker","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101311_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacl.2017.09.007","article-title":"A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)","volume":"12","author":"Koh","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101311_bib0017","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101311_bib0018","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"issue":"43","key":"10.1016\/j.ajpc.2025.101311_bib0019","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101311_bib0020","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101311_bib0021","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of Evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101311_bib0023","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101311_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101311_bib0025","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101311_bib0026","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101311_bib0027","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ajpc.2025.101311_bib0028","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101311_bib0029","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of Alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome \u2015 the ODYSSEY J-IVUS trial \u2015","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101311_bib0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of Evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101311_bib0033","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101311_bib0034","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101311_bib0036","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1592\/phco.31.11.1051","article-title":"Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"31","author":"Wang","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101311_bib0037","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2007.09.063","article-title":"Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials","volume":"51","author":"Fauchier","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101311_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ihj.2023.01.004","article-title":"Prior statin use and the incidence of in-hospital arrhythmia in acute coronary syndrome: a systematic review and meta-analysis","volume":"75","author":"Wibawa","year":"2023","journal-title":"Indian Heart J"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101311_bib0039","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ijcard.2012.11.087","article-title":"Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study","volume":"168","author":"Hung","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101311_bib0040","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/ijms22063144","article-title":"Pleiotropic effects of PCSK-9 inhibitors","volume":"22","author":"Basiak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101311_bib0041","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/metabo12030226","article-title":"Pleiotropic effects of PCSK9: focus on thrombosis and haemostasis","volume":"12","author":"Puccini","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.ajpc.2025.101311_bib0042","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jare.2023.09.007","article-title":"Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling","volume":"61","author":"Han","year":"2024","journal-title":"J Adv Res"},{"key":"10.1016\/j.ajpc.2025.101311_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104087","article-title":"Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis","volume":"82","author":"Luo","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajpc.2025.101311_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101311_bib0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.amjcard.2007.07.015","article-title":"Meta-analysis of effect of Statin treatment on risk of sudden death","volume":"100","author":"Levantesi","year":"2007","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.ajpc.2025.101311_bib0046","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/eurheartj\/ehs005","article-title":"Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials","volume":"33","author":"Rahimi","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101311_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171168","article-title":"No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"12","author":"Al-Gobari","year":"2017","journal-title":"PLoS One"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725003861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725003861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:49:23Z","timestamp":1765446563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725003861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S2666667725003861"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101311","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between proprotein convertase subtilisin\/kexin type 9 targeted therapies and the risk of arrhythmias: a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101311"}}